Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.83 +1.9%	$1.81	$1.29 ▼ $13.07	$108.90M	-0.14	683,092 shs	343,689 shs
CLBS Caladrius Biosciences		$6.37	$0.38 ▼ $1.24	$26.05M	0.91	522,308 shs	466,373 shs
HLVX HilleVax	$2.06 -0.5%	$2.04	$1.34 ▼ $2.17	$103.29M	0.77	981,770 shs	480,165 shs
IZTC Invizyne Technologies	$9.31	$10.17	$8.50 ▼ $23.00	$58.21M	N/A	37,647 shs	794 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	0.00%	+5.78%	+1.10%	+23.65%	-70.81%
CLBS Caladrius Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
HLVX HilleVax	0.00%	-0.96%	-3.74%	+10.75%	+3.00%
IZTC Invizyne Technologies	0.00%	-4.02%	+0.65%	-37.52%	+930,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	3.6483 of 5 stars	4.6	3.0	0.0	0.0	2.0	2.5	0.6
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	1.1417 of 5 stars	1.0	4.0	0.0	0.0	0.0	3.3	1.3
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.17	Buy	$16.80	818.03% Upside
CLBS Caladrius Biosciences	0.00	N/A	N/A	N/A
HLVX HilleVax	2.00	Hold	$2.00	-2.91% Downside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLBS, BMEA, HLVX, and IZTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/8/2025	HLVX HilleVax	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	$3.10 per share	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
CLBS Caladrius Biosciences	-$27.47M	-$0.41	N/A	N/A	N/A	N/A	-27.24%	-26.08%	N/A
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	11/6/2025 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CLBS, BMEA, HLVX, and IZTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	HLVX HilleVax	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.68	3.68
CLBS Caladrius Biosciences	N/A	22.33	22.33
HLVX HilleVax	N/A	26.39	26.39
IZTC Invizyne Technologies	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
CLBS Caladrius Biosciences	15.57%
HLVX HilleVax	86.42%
IZTC Invizyne Technologies	N/A

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
CLBS Caladrius Biosciences	2.20%
HLVX HilleVax	24.90%
IZTC Invizyne Technologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
CLBS Caladrius Biosciences	27	60.58 million	59.25 million	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A

CLBS, BMEA, HLVX, and IZTC Headlines

Recent News About These Companies

Invizyne Technologies (NASDAQ:IZTC) Stock Price Up 0.6% - Still a Buy?

August 21 at 3:04 AM | marketbeat.com

Invizyne Technologies (NASDAQ:IZTC) Shares Up 4.7% - Should You Buy?

July 26, 2025 | marketbeat.com

Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)

February 13, 2025 | uk.finance.yahoo.com

What’s in a Name: Out with Invizyne, In with eXoZymes

February 12, 2025 | genengnews.comG

Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ

February 11, 2025 | msn.com

Invizyne announces corporate name change to eXoZymes

February 11, 2025 | markets.businessinsider.com

Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%

February 4, 2025 | aaii.comA

Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%

January 30, 2025 | aaii.comA

Invizyne technologies CEO Michael Heltzen buys $20,345 in stock

January 21, 2025 | msn.com

Invizyne Technologies Inc trading resumes

January 1, 2025 | markets.businessinsider.com

Invizyne Technologies Inc trading halted, volatility trading pause

January 1, 2025 | markets.businessinsider.com

Michael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) Stock

November 20, 2024 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLBS, BMEA, HLVX, and IZTC Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.83 +0.04 (+1.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.81 -0.02 (-1.04%)

As of 08/22/2025 07:56 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Caladrius Biosciences NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

HilleVax NASDAQ:HLVX

$2.06 -0.01 (-0.48%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.06 +0.00 (+0.24%)

As of 08/22/2025 07:17 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Invizyne Technologies NASDAQ:IZTC

$9.31 0.00 (0.00%)

As of 08/22/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time